Corporate-legal instruments in transactions involving pharmaceutical assets
In 2025, the pharmaceutical market grew, and the number of transactions in it increased sharply. The high cost of borrowed capital, strict regulation and a valuation gap have made the legal structure of a transaction no less important than its price. The authors examine how Russian corporate law instruments work in the pharmaceutical industry — from the purchase of a pharmacy chain to a joint venture for product localisation.